Bioxyne Limited (AU:BXN)

ASX:BXN

BXN

Bioxyne Limited

RESEARCH TOOLSreports

Want to see AU:BXN full AI Analyst Report?

Bioxyne Limited (BXN) Price & Analysis

Q: What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was AU$0.03 and its highest was AU$0.11 in the past 12 months.

Q: What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$240.56M.

Q: When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 66 days.

Q: How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.

Q: Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

Q: What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,291,036,000 shares outstanding.

Q: What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.

Q: Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

16 Followers

BXN Stock Chart & Stats

AU$0.04

<AU$0.01(4.17%)

At close: Jan 09 4:00 PM EST

AU$0.04

<AU$0.01(4.17%)

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.11

Previous CloseN/A

Volume631.90K

Average Volume (3M)4.35M

Market Cap

AU$240.56M

Enterprise ValueAU$228.67M

Total Cash (Recent Filing)AU$7.60M

Total Debt (Recent Filing)AU$7.43M

Price to Earnings (P/E)26.1

Beta1.52

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding2,291,036,000

10 Day Avg. Volume2,483,521

30 Day Avg. Volume4,348,514

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)7.54

Price to Sales (P/S)2.90

P/FCF Ratio22.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth & Market DemandSustained 77% revenue growth indicates expanding product adoption and market penetration in regulated medicinal cannabis. Over 2-6 months this underpins higher scale, stronger distribution relationships and improved bargaining power with suppliers and customers, supporting durable top-line momentum.

Improved ProfitabilityMaterial improvement in net and EBIT margins reflects better cost control and operational execution. Higher profitability increases reinvestment capacity, resilience to cost pressures, and ability to fund product development and commercialization without reliance on external capital over the medium term.

Strong Cash GenerationA large free cash flow rebound and solid cash conversion ratios materially improve financial flexibility. Durable cash generation reduces refinancing risk, funds working capital and capex for cultivation/manufacturing, and creates optionality for strategic investments or partnerships over the next several quarters.

Bears Say

Moderate Gross MarginA mid-30s gross margin limits the cushion available to absorb input cost inflation and channel discounts. To sustain long-term margin expansion the company must improve procurement, yields or product mix; otherwise operating leverage from revenue growth could be constrained over multiple quarters.

Regulatory DependenceRevenue and market access hinge on regulatory approvals and prescribing rules in medicinal cannabis. Regulatory shifts or slow product registrations create structural revenue variability and longer commercialization timelines, increasing execution risk and limiting predictable expansion.

Small Scale & Concentration RiskA very small workforce relative to the breadth of cultivation, manufacturing and distribution activities raises operational concentration risk. Limited internal capacity can slow new product launches, strain compliance and scalability, and increase reliance on third parties for critical functions over the medium term.

Bioxyne Limited News

Bioxyne to List 2.64 Million New Ordinary Shares on ASX

An update from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited has applied for quotation on...

4d ago

BXN

Bioxyne shareholders back name change and capital consolidation

Bioxyne Limited ( ($AU:BXN) ) has shared an announcement. Bioxyne Limited has announced that all resolutions put to...

4d ago

BXN

Bioxyne Calls Shareholder Vote on Name Change and Capital Consolidation

Bioxyne Limited ( ($AU:BXN) ) just unveiled an announcement. Bioxyne Limited has scheduled a general meeting of shareholders...

5d ago

BXN

Bioxyne Appoints Edward Myer to Board With No Declared Shareholding

An update from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited has appointed Edward Myer as...

18d ago

BXN

Bioxyne strengthens board with appointment of independent director Edward Myer

Bioxyne Limited ( ($AU:BXN) ) has shared an update. Bioxyne has appointed experienced investor and executive Edward Myer...

20d ago

BXN

Bioxyne to Outline Global Psychedelic and Cannabis Strategy at Coffee Microcaps Webinar

Bioxyne Limited ( ($AU:BXN) ) just unveiled an update. Bioxyne Limited, an Australian pharmaceutical company, develops and commercialises...

22d ago

BXN

Bioxyne seeks ASX quotation for nearly 7 million new shares

An update from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited has applied for quotation on...

28d ago

BXN

Bioxyne to Consolidate Shares, Options and Performance Rights

An announcement from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited has announced a consolidation of...

1M ago

BXN

Bioxyne calls June shareholder meeting as it leans into digital engagement and alternative therapeutics

Bioxyne Limited ( ($AU:BXN) ) has provided an announcement. Bioxyne Limited has called a General Meeting of shareholders...

1M ago

BXN

Bioxyne calls June 2026 general meeting, urges proxy voting

The latest update is out from Bioxyne Limited ( ($AU:BXN) ). Bioxyne Limited has called a General Meeting...

1M ago

BXN

BXN FAQ

What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was AU$0.03 and its highest was AU$0.11 in the past 12 months.

What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$240.56M.

When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 66 days.

How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.

Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,291,036,000 shares outstanding.

What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.

Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bioxyne Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

56.29%

Trailing 12-Months

Asset Growth

131.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioxyne Limited

Headquartered in Sydney, Australia, Bioxyne Limited is a life sciences and health company established in 1998. The firm dedicates itself to the research, development, marketing, and distribution of nutritional supplements and beauty products. Its operations are divided into wholesale and direct sales segments, reaching customers online, through partners, and directly across the United States and Asia. Bioxyne's diverse product line includes functional foods and cosmetic solutions, notably Progastrim for digestive and immune wellness, Progastrim plus Vitamin C for cold symptom relief, and proTract, specifically formulated for infant eczema (atopic dermatitis).